Bullish
AstraZeneca surpassed first-quarter sales and profit estimates, largely due to strong demand for its cancer drugs. The company reaffirmed its 2026 fin...
Bullish
AstraZeneca's strong oncology portfolio, featuring drugs like Tagrisso and Enhertu, positions it well to meet rising global healthcare needs, particul...
Neutral
AstraZeneca PLC has established a strong position in the pharmaceutical industry, particularly in oncology, with key drugs like Enhertu and Imfinzi dr...
Neutral
Astrazeneca (AZN) stock saw a 1.55% decline in the latest trading session, underperforming the S&P 500's gain. Despite this, its shares have appreciat...
Bullish
AstraZeneca India plans to sell its 64-acre manufacturing facility in North Bengaluru for approximately INR 3,400 crore. This divestment is part of a ...
Neutral
Venturi Wealth Management LLC lifted its position in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 9.6% during the 4th quarter, according to i...